Loading...
Bilateral Trade Intelligence · $11.0K Total Trade · 7 Foreign Suppliers · 6 Indian Buyers · DGFT Verified · Updated March 2026
India imported $11.0K worth of pharmaceutical formulations from Georgia across 18 verified shipments, from 7 foreign suppliers to 6 Indian buyers. The top suppliers are HEMOLINE LTD ($7.3K) and J.S.C. K. ERISTAVI NATIONAL CENTER OF ($2.0K). The leading products are Plasma ($11K) and Valsartan ($240). Average shipment value: $610.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Plasma | $10.7K | 97.2% |
| 2 | Valsartan | $240 | 2.2% |
| 3 | Tofacitinib | $63 | 0.6% |
India imports 3+ pharmaceutical formulations from Georgia with a combined trade value of $11.0K. Key products include Plasma ($11K), Valsartan ($240), Tofacitinib ($63). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 18 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Georgia, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Georgia buyers, regulatory requirements, and logistics for that specific product corridor. Products include Plasma ($11K), Valsartan ($240), Tofacitinib ($63) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Georgia and India has experienced modest activity from 2022 to 2026. In 2022, India imported pharmaceutical products valued at approximately $11,000 USD from Georgia, comprising 18 shipments from 7 Georgian suppliers to 6 Indian buyers. The average shipment value stood at $610 USD. The primary product imported was plasma, accounting for 97.2% of the total import value, followed by valsartan at 2.2%, and tofacitinib at 0.6%. The leading Georgian supplier was HEMOLINE LTD, contributing $7,000 USD through a single shipment, while the top Indian buyer was INTAS PHARMACEUTICALS LTD., importing goods worth $7,000 USD in one shipment.
Georgia's contribution to India's pharmaceutical imports remains relatively minor. In 2024, India imported pharmaceutical products from Georgia valued at $361,600 USD, a slight increase from the $59,900 USD recorded in 2022. This indicates a gradual expansion in trade volume, albeit from a low base. The imports predominantly consist of finished pharmaceutical formulations, with plasma being the most significant product category.
7 Indian pharmaceutical companies export finished formulations to Georgia. Leading exporters include Hemoline Ltd, J.s.c. K. Eristavi National Center Of, Llc Caucasus Medical Centre, Gm Pharmaceuticals Ltd. The top exporter accounts for 66.1% of total India–Georgia pharma exports. Source: Indian Customs (DGFT).
6 companies in Georgia import pharmaceutical formulations from India. Top buyers include Intas Pharmaceuticals Ltd., Watson Pharma Private Limited, Veeda Clinical Research Limited, Lambda Therapeutic Research Limited. The largest buyer accounts for 66.1% of India–Georgia pharma imports. Source: Indian Customs (DGFT).
Between 2024 and 2026, there have been no significant policy changes by the Central Drugs Standard Control Organisation (CDSCO) specifically targeting imports from Georgia. Trade agreements or regulatory harmonization efforts affecting this bilateral trade have not been prominently reported. The trade volume remains limited, suggesting that both countries have not prioritized enhancing this specific trade corridor.
Registration process, GMP requirements, import documentation
For Georgian pharmaceutical companies aiming to export to India, obtaining approval from the CDSCO is mandatory. The process involves registering on the CDSCO's SUGAM portal, submitting an Integrated Registration Form (IRF), and providing necessary documents such as an undertaking form, valid address proof of the firm, and a valid ID proof of the authorized person. The timeline for approval can vary, but it typically spans several months, depending on the completeness and accuracy of the submitted documentation. Clinical trial waivers may be granted under specific conditions, particularly if the product has been approved in other recognized markets.
India requires that pharmaceutical products imported from Georgia adhere to Good Manufacturing Practice (GMP) standards. Manufacturing sites in Georgia must be WHO-GMP certified to ensure product quality and safety. The CDSCO conducts inspections to verify compliance with these standards. Non-compliance can result in delays or rejections of import applications.
Importing pharmaceutical products into India necessitates obtaining an import license (Form 10) from the CDSCO. Additional required documents include a registration certificate, No Objection Certificate (NOC), test license, and adherence to customs procedures. These documents ensure that the imported products meet Indian regulatory standards and are safe for public use.
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical imports from Georgia to India are predominantly in the form of finished pharmaceutical formulations. Plasma is the leading product category, followed by valsartan and tofacitinib. This suggests a focus on specific therapeutic areas, with plasma products being particularly significant.
The imports from Georgia include specialized pharmaceutical products such as plasma, valsartan, and tofacitinib. These products are not widely manufactured domestically in India, indicating a reliance on imports for certain specialized treatments.
India's imports from Georgia are driven by factors such as the need for specialized pharmaceutical products not available domestically, quality considerations, and the desire to diversify sources of supply. The relatively low volume of trade suggests that these factors are not yet major drivers but could become more significant with increased demand for specialized treatments.
Tariff structure, trade agreements, IP and patent landscape
India's import tariff structure for pharmaceutical formulations includes the Most Favored Nation (MFN) tariff rates, basic customs duty, Integrated Goods and Services Tax (IGST), and health cess. These tariffs are subject to change based on government policies and international trade agreements. Specific rates can vary, and it is advisable to consult the latest notifications from the Directorate General of Foreign Trade (DGFT) for current information.
As of March 2026, there are no specific Free Trade Agreements (FTAs) or preferential duty rates between India and Georgia concerning pharmaceutical imports. Both countries are members of the Regional Comprehensive Economic Partnership (RCEP), but the impact of this agreement on bilateral pharmaceutical trade remains limited.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, influences the import of pharmaceutical products. This section restricts the patentability of new forms of known substances unless they result in enhanced efficacy. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential drugs, which can affect the pricing of imported pharmaceuticals.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from Georgia to India typically utilize sea routes, with transit times varying based on the specific ports of departure and arrival. Air freight is also an option, offering faster delivery times but at higher costs. The reliability of these routes is generally high, but factors such as geopolitical events and weather conditions can impact schedules.
In Georgia, pharmaceutical exports are handled through major ports such as the Port of Batumi and the Port of Poti. In India, ports like Mumbai and Chennai are equipped to handle pharmaceutical imports, ensuring compliance with regulatory standards and maintaining product integrity during transit.
Indian customs procedures for pharmaceutical imports involve clearance by the Directorate General of Foreign Trade (DGFT) and the CDSCO. Imported pharmaceuticals must comply with cold chain requirements to maintain product efficacy, especially for temperature-sensitive products like plasma. Good Distribution Practice (GDP) compliance is mandatory to ensure the quality and safety of imported pharmaceutical products.
Market size, healthcare system, growth outlook
Despite being a major pharmaceutical manufacturer, India imports specialized products such as plasma, valsartan, and tofacitinib from Georgia. This dependency is due to the lack of domestic production capabilities for these specific products and the need to meet diverse patient requirements.
Georgian pharmaceutical companies exporting to India include HEMOLINE LTD, J.S.C. K. ERISTAVI NATIONAL CENTER OF, LLC CAUCASUS MEDICAL CENTRE, GM PHARMACEUTICALS LTD, and CROMOS PHARMA GEORGIA LTD. These companies focus on supplying specialized pharmaceutical products to the Indian market, often through direct exports.
India's Atmanirbhar Bharat initiative and the Production Linked Incentive (PLI) scheme aim to boost domestic pharmaceutical manufacturing. While these efforts may reduce the need for imports in some areas, the demand for specialized products not manufactured domestically is likely to sustain imports from countries like Georgia.
Competing origins, India's edge, challenges and threats
India imports pharmaceuticals from various countries, including the USA, EU, China, Switzerland, and Japan. In 2024, India's pharmaceutical imports from Georgia were valued at $361,600 USD, compared to $2.93 million USD from the USA, $2.4 million USD from the EU, and $29.06 million USD from China. This indicates that Georgia's share in India's pharmaceutical imports is relatively small.
Indian buyers may choose Georgian pharmaceutical products due to factors such as the availability of specialized products not manufactured domestically, competitive pricing, and the quality standards maintained by Georgian manufacturers.
Indian pharmaceutical manufacturers are increasingly developing alternatives to imported products, including biosimilars and generic versions of patented drugs. The PLI scheme has incentivized domestic production, potentially reducing the market share for imported pharmaceuticals from countries like Georgia.
India exported pharmaceuticals worth $11.0K to Georgia across 18 verified shipments.
1. HEMOLINE LTD — $7.3K. 2. J.S.C. K. ERISTAVI NATIONAL CENTER OF — $2.0K. 3. LLC CAUCASUS MEDICAL CENTRE — $1.3K. Total: 7 suppliers.
1. INTAS PHARMACEUTICALS LTD. — $7.3K. 2. WATSON PHARMA PRIVATE LIMITED — $3.3K. 3. VEEDA CLINICAL RESEARCH LIMITED — $240. 6 buyers total.
1. Plasma ($10.7K, 97.2%); 2. Valsartan ($240, 2.2%); 3. Tofacitinib ($63, 0.6%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $11.0K corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$610 per consignment across 18 shipments.
7 Indian companies. Largest: HEMOLINE LTD with $7.3K.
TransData Nexus covers 7 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 18 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
7 Exporters
6 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists